For the Quarter Ending March 2026
Lisinopril Prices in North America
- In United States, the Lisinopril Price Index rose quarter-over-quarter in Q1 2026, driven by surging production costs.
- In March 2026, the Consumer Price Index rose 3.3% and Producer Price Index increased 4.0% year-over-year.
- Industrial production grew 0.7% year-over-year in March 2026, while the Manufacturing Index expanded, ensuring steady pharmaceutical output.
- Retail sales increased 4.0% year-over-year and the unemployment rate stabilized at 4.3% in March 2026.
- Consumer confidence reached 91.8 in March 2026, which supported a robust Lisinopril Demand Outlook across retail pharmacies.
- The Lisinopril Production Cost Trend surged in March 2026 as upstream petrochemical feedstock and energy inflation spiked.
- Lisinopril oral solution inventories tightened at retail pharmacies in February 2026 due to single-manufacturer dependency constraints.
- Global API supply chain restructuring accelerated and healthcare hospital M&A activity strengthened during Q1 2026.
- The Lisinopril Price Forecast reflected upward pressure as the Lisinopril Price Index climbed throughout Q1 2026.
Why did the price of Lisinopril change in March 2026 in North America?
- Upstream petrochemical feedstock costs and regional energy inflation surged across North America in March 2026.
- Severe logistics disruptions escalated, increasing distribution overhead for pharmaceuticals across North America in March 2026.
- Generic pharmaceutical orders for Lisinopril dihydrate API surged robustly across the region in Q1 2026.
Lisinopril Prices in APAC
- In China, the Lisinopril Price Index rose quarter-over-quarter in Q1 2026, driven by surging L-Lysine feedstock costs.
- The Producer Price Index increased by 0.5% in March 2026, creating cost-push inflation for Lisinopril production.
- A 1.0% Consumer Price Index rise and 1.7% retail sales growth in March 2026 supported generic demand.
- An unemployment rate of 5.4% in March 2026 and consumer confidence at 91.6 in February 2026 boosted generic Lisinopril.
- Industrial production grew 5.7% and the Manufacturing Index expanded in March 2026, ensuring abundant API supply.
- The Lisinopril Demand Outlook strengthened throughout Q1 2026 due to the rising prevalence of chronic cardiovascular disorders.
- The Lisinopril Production Cost Trend escalated as L-Lysine feedstock export costs surged significantly in March 2026.
- Downstream terminals focused on existing inventory drawdowns in March 2026, despite robust L-Lysine export activities.
- The Lisinopril Price Forecast reflected sustained cost pressures in Q1 2026, although stabilized energy costs moderated expenses.
Why did the price of Lisinopril change in March 2026 in APAC?
- L-Lysine feedstock export costs surged in March 2026, directly increasing active pharmaceutical ingredient manufacturing expenses.
- The Producer Price Index increased by 0.5% in March 2026, driving cost-push inflation across markets.
- Leading L-Lysine feedstock producers suspended quotations in March 2026, tightening supply for domestic pharmaceutical synthesis.
Lisinopril Prices in Europe
- In Germany, the Lisinopril Price Index rose quarter-over-quarter in Q1 2026, driven by surging energy costs.
- The Lisinopril Production Cost Trend increased in March 2026 as inflation reached 2.7 percent year-over-year.
- Despite the rising Lisinopril Price Index, producer prices declined by -0.2 percent year-over-year in March 2026.
- The Manufacturing Index expanded in March 2026, supporting a stable Lisinopril Demand Outlook across the region.
- Industrial production remained stagnant at 0.0 percent year-over-year in February 2026, constraining domestic pharmaceutical manufacturing supply.
- Retail sales grew 0.7 percent and unemployment stayed at 4.2 percent in February 2026, sustaining consumption.
- Consumer confidence dropped to -24.7 in March 2026, causing cautious spending behavior within the pharmaceutical sector.
- Natural gas feedstock costs for L-lysine fermentation plummeted initially in Jan-Feb 2026 before spiking abruptly.
- The Lisinopril Price Forecast reflected upward pressure in March 2026 following severe global energy supply disruptions.
Why did the price of Lisinopril change in March 2026 in Europe?
- Energy-intensive manufacturing expenses surged in March 2026 following Middle East supply disruptions and geopolitical conflicts.
- European underground natural gas storage levels depleted significantly by March 2026 due to colder winter conditions.
- Cross-basin competition for energy cargoes intensified between Europe and Asia in March 2026, altering trade.
For the Quarter Ending December 2025
Lisinopril Prices in North America
- In United States, the Lisinopril Price Index rose in Q4 2025, influenced by increasing production costs and robust pharmaceutical market performance.
- Lisinopril production costs increased due to a 3.0% year-over-year rise in producer prices in November 2025.
- Overall consumer prices increased 2.7% year-over-year in December 2025, impacting raw material and energy expenses.
- The pharmaceutical market outperformed in Q4 2025, indicating strong demand for essential medications like Lisinopril.
- Higher borrowing costs constrained chemical companies in Q4 2025, influencing Lisinopril production expenses.
- A 4.4% unemployment rate in December 2025 supported patient access to healthcare, bolstering Lisinopril demand.
- US chemical output contracted in October 2025, while pharmaceutical preparations imports decreased that month.
- North American chemical producers benefited from abundant low-cost shale gas feedstock throughout 2025.
Why did the price of Lisinopril change in December 2025 in North America?
- Producer prices increased 3.0% year-over-year in November 2025, raising Lisinopril manufacturing input costs.
- Consumer prices rose 2.7% year-over-year in December 2025, contributing to higher operational expenses.
- The pharmaceutical sector outperformed in Q4 2025, supporting demand despite broader chemical output contraction.
Lisinopril Prices in Europe
- In Germany, the Lisinopril Price Index fell quarter-over-quarter in Q4 2025, influenced by a -2.5% Producer Price Index in December 2025.
- Lisinopril production costs faced downward pressure in Q4 2025 due to declining wholesale natural gas and electricity prices by year-end 2025.
- Demand for Lisinopril remained steady in Q4 2025, supported by robust prescription volumes and an aging population.
- Low capacity utilization in the German chemical industry during Q4 2025 indicated elevated Lisinopril inventory levels.
- Intensified competitive pressure from abroad in Q4 2025, with declining German chemical exports, impacted market dynamics.
- The German Chemical Industry Business Climate deteriorated sharply in October 2025, reflecting weak domestic and export orders.
- Stable consumer prices, with CPI at 1.8% year-on-year in December 2025, supported general affordability for pharmaceuticals.
- A contracting Manufacturing Index in December 2025 and a 6.2% unemployment rate impacted overall healthcare spending.
Why did the price of Lisinopril change in December 2025 in Europe?
- The Producer Price Index fell by -2.5% year-on-year in December 2025, reducing Lisinopril input costs.
- Competitive pressure from abroad intensified in Q4 2025, with concerns about cheaper chemical products.
- Wholesale natural gas and electricity prices declined significantly by year-end 2025, lowering production expenses.
Lisinopril Prices in APAC
- In China, the Lisinopril Price Index remained stable in Q4 2025, influenced by weak consumer demand.
- Lisinopril production costs declined in December 2025, as producer prices for industrial products fell by 1.9% year-over-year.
- Lisinopril demand outlook was stable in Q4 2025, despite weak retail sales growth of 0.9% in December 2025.
- China's manufacturing index expanded in December 2025, supporting stable Lisinopril supply chains.
- Industrial production grew robustly by 5.2% year-over-year in December 2025, ensuring stable Lisinopril supply.
- Lisinopril inventory levels remained elevated in Q4 2025 due to global overcapacity in chemical building blocks.
- China's medicine exports, including active pharmaceutical ingredients, increased during 2025.
- Weak consumer confidence in Q4 2025, with 0.8% CPI in December 2025, limited Lisinopril pricing power.
- The pharmaceutical sector in China focused on higher value-added products in 2025, influencing market dynamics.
Why did the price of Lisinopril change in December 2025 in APAC?
- Producer prices for industrial products declined by 1.9% year-over-year in December 2025, reducing Lisinopril costs.
- Weak consumer demand, with 0.9% retail sales growth in December 2025, limited Lisinopril pricing.
- Elevated global chemical overcapacity in Q4 2025 contributed to stable or downward pressure on Lisinopril prices.
For the Quarter Ending September 2025
Lisinopril Prices in North America
- In the United States, the Lisinopril Price Index rose quarter-over-quarter in Q3 2025, driven by inflationary pressures.
- Lisinopril production costs increased due to a 3.0% year-over-year CPI in September 2025 and strengthening industrial electricity prices.
- Demand for Lisinopril was supported by a 5.42% year-over-year retail sales rise in September 2025 and strong pharmaceutical market sentiment.
- The Lisinopril Price Forecast indicates upward pressure from rising producer costs, with PPI up 2.6% year-over-year in August.
- Lisinopril demand outlook remains positive, bolstered by projected increases in national health spending for 2025.
- Tightening US manufacturing inventories and sluggish 0.1% year-over-year industrial production in September 2025 impacted supply.
- Primary basic organic chemical prices decreased in September 2025, offering some cost relief for Lisinopril production.
- A 4.3% unemployment rate in September 2025 and declining consumer confidence presented slight headwinds for patient affordability.
Why did the price of Lisinopril change in September 2025 in North America?
- Rising producer costs, with PPI up 2.6% year-over-year in August 2025, pressured Lisinopril prices upward.
- Strong consumer spending, retail sales up 5.42% year-over-year in September 2025, supported Lisinopril demand.
- Decreased primary basic organic chemical prices in September 2025 offered some relief to production costs.
Lisinopril Prices in APAC
- In China, the Lisinopril Price Index remained stable quarter-over-quarter in Q3 2025, influenced by mixed macroeconomic signals.
- Lisinopril production costs faced upward pressure in Q3 2025 due to high fine chemical production expenses.
- Lisinopril demand outlook was supported by China's expanding healthcare market during Q3 2025.
- In September 2025, the Consumer Price Index declined by 0.3%, signaling broader economic deflationary trends.
- The Producer Price Index fell by 2.3% in September 2025, indicating lower factory-gate prices for some inputs.
- China's Manufacturing Index was contracting in September 2025, impacting overall supply chain stability.
- Industrial production grew by 6.5% in September 2025, supporting a stable pharmaceutical manufacturing environment.
- Retail sales increased by 3.0% in September 2025, indirectly bolstering medication affordability and demand.
- Natural gas consumption declined in the first half of 2025, impacting production costs for some chemical inputs.
- Trade flows exhibited resilience in Q3 2025, with increased exports and port cargo throughput.
Why did the price of Lisinopril change in September 2025 in APAC?
- Deflationary pressures from a 0.3% Consumer Price Index decline in September 2025 influenced pricing power.
- High production costs in the fine chemicals market during Q3 2025 exerted upward pressure on manufacturing expenses.
- China's expanding healthcare market in Q3 2025, driven by an aging population, supported demand.
Lisinopril Prices in Europe
- In Germany, the Lisinopril Price Index fell quarter-over-quarter in Q3 2025, driven by weakened European chemical producer prices.
- Lisinopril production costs declined in September 2025 as producer prices fell by 1.7% year-on-year.
- Rising CPI (2.4%) in September 2025 and elevated energy costs challenged Lisinopril production expenses.
- Lisinopril demand remained sustained in 2025 due to Germany's aging population and rising chronic diseases.
- The Manufacturing Index contracted in September 2025, signaling a weaker industrial environment.
- Industrial production declined by 1.0% year-on-year in September 2025, impacting Lisinopril supply chain.
- Fragile Active Pharmaceutical Ingredient imports introduced margin pressure for Lisinopril manufacturers in 2025.
- US tariffs significantly impacted German companies' US chemical and pharmaceutical business in July 2025.
- Consumer confidence significantly deteriorated to -23.6 in September 2025, indicating broader economic pessimism.
Why did the price of Lisinopril change in September 2025 in Europe?
- Producer prices declined by 1.7% year-on-year in September 2025, reducing Lisinopril manufacturing input costs.
- The Manufacturing Index contracted in September 2025, reflecting a slowdown in overall industrial activity.
- Structurally elevated energy costs and rising electricity prices in Q3 2025 pressured Lisinopril production expenses.
For the Quarter Ending December 2022
North America
As per the data, Lisinopril prices across the United States market dropped around 3.6% during the fourth quarter of 2022 due to bearish demand from end-user pharmaceutical and healthcare industries coupled with adequate product availability among domestic retailers.
The reason behind the accumulation was that domestic merchants had excessive imports from Asia as they had placed their orders in advance. In order to increase the inquiries from the end user sector and to clear their existing stockpiles, suppliers gradually reduced their quotations. All these factors combinedly resulted in a declining price trend in the US domestic market and with prices settled at around USD 319500/MT by the end of the quarter.
Asia- Pacific
In the fourth quarter of 2022, the price trend for Lisinopril in the Asia Pacific market fluctuated. The market opened in October with bearish sentiments but enhanced in November, with prices settling at USD 297800/MT. The market supply side faced great uncertainty in the H1 of Q4, mainly due to the halt in production activities amid the Golden week holiday and Covid-19 restrictions. These factors caused an escalation in the prices of Lisinopril in November. Later, the upward trend declined in the last weeks of the quarter, with prices assembling at USD 289700/MT. Despite the ease in China's zero-COVID strategy in early December, the demand for Lisinopril was not improved throughout the month. Also, the trading activities were muted due to low inquiries from overseas buyers ahead of the year-end holidays.
Europe
During Q4 of 2022, the prices of Lisinopril resembled the trend of the Asia-Pacific region. The price of Lisinopril first decreased by 1.3% in October but later increased significantly by 2% in November, with values settling at USD 344200 /MT. In October, the lack of inquiries from the downstream pharmaceutical sector dampened the market sentiments for Lisinopril in the German domestic market. However, in the mid-quarter, the increment in Lisinopril prices was driven by low supply from Asian countries. Moreover, rising concerns about the economy and the high inflation rate in Europe impact the overall price of the product. Therefore, by the termination of Q4, the dynamics of the Lisinopril market were again suppressed as purchasing activities across the German domestic market dropped, with prices evaluated at USD 338750/MT.
